stockrow
Friday 6 November 2026
Export SRPT’s income statement to Excel — free account
Sarepta Therapeutics, Inc.
SRPT Healthcare Biotechnology
Sarepta Therapeutics, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $2.2 billion, up 15.6% from fiscal 2024.
- Revenue
- −4.51%
- EPS
- +46.0%
- Free cash flow
- +231.8%
- Total debt
- −17.2%
Quarter to September 2026, against a year earlier
17.71
0.14
+0.80%
Follow SRPT
Alert me
| Older periods | Dec '25 | Mar '26 | Jun '26 | Sep '26 From the 10-Q filed 5 Nov | |
|---|---|---|---|---|---|
P/E ratio |
+8 more quarters Free account |
0.00 | 29.81 | 0.00 | 0.00 |
P/S ratio |
0.98 | 1.05 | 0.96 | 0.99 | |
P/FCF ratio |
0.00 | 21.11 | 25.27 | 11.39 | |
P/Operating CF |
16.42 | (11.27) | 9.61 | 32.19 | |
P/B ratio |
1.89 | 1.52 | 1.24 | 1.26 | |
Price to Tangible BV |
1.91 | 1.53 | 1.25 | 1.27 | |
EV/Sales |
0.97 | 1.17 | 1.04 | 0.98 | |
EV/EBITDA |
0.00 | 9,628.22 | 0.00 | 0.00 | |
EV/Operating CF |
(10.39) | 14.61 | 18.43 | 10.29 | |
EV/FCF |
(6.77) | 23.66 | 27.28 | 11.26 | |
Quick Ratio |
1.22 | 2.10 | 2.32 | 1.90 | |
Current Ratio |
2.32 | 4.63 | 4.42 | 3.46 | |
Net Debt/EBITDA |
0.27 | 0.50 | 2.59 | 0.00 | |
Debt/Assets |
24.75% | 26.37% | 26.58% | 27.08% | |
Debt/Equity |
0.73 | 0.56 | 0.55 | 0.56 | |
Asset Turnover |
0.60 | 0.66 | 0.57 | 0.59 | |
Operating CF/Net income |
(0.32) | (0.61) | (40.30) | (2.11) | |
Capex/Depreciation |
(0.77) | (0.31) | (0.06) | 0.00 | |
Research and Development Expense of Revenue |
73.45% | 21.07% | 22.74% | 21.65% | |
Selling, General and Administrative Expense of Revenue |
28.97% | 14.91% | 26.82% | 31.10% | |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 | 0.00 | |
Share Based Compensation of Revenue |
6.78% | 4.02% | 6.10% | 7.01% | |
Graham Net Nets |
0.15 | 0.28 | 0.30 | 0.33 | |
Graham Number |
0.00 | 15.35 | 0.00 | 0.00 | |
Earnings Yield |
(32.62%) | 3.35% | (7.40%) | (6.04%) | |
Free Cash Flow Yield |
(14.64%) | 4.74% | 3.96% | 8.78% | |
Revenue per Share |
4.42 | 6.96 | 3.81 | 3.60 | |
Operating CF per Share |
1.31 | (1.93) | 1.87 | 0.57 | |
Capex per Share |
(0.04) | (0.03) | (0.01) | (0.03) | |
Free Cash Flow per Share |
1.27 | (1.96) | 1.86 | 0.54 | |
Cash per Share |
9.39 | 6.22 | 7.48 | 8.30 | |
Shareholders Equity per Share |
11.39 | 14.34 | 14.49 | 14.43 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
11.39 | 14.34 | 14.49 | 14.43 | |
Free Cash Flow |
127.48 | (205.76) | 196.52 | 57.03 | |
Working Capital |
1,442.65 | 1,810.71 | 1,720.92 | 1,616.54 | |
Capital Expenditures |
(3.73) | (3.08) | (0.55) | (2.93) | |
Net Current Asset Value |
328.86 | 636.04 | 563.11 | 635.68 | |
EV/EBIT |
0.00 | 0.00 | 0.00 | 0.00 | |
Capex to Sales |
0.01 | 0.00 | 0.00 | 0.01 | |
Price to Operating Income |
0.00 | 0.00 | 0.00 | 0.00 | |
| Other line items | |||||
Average Receivables |
500.11 | 527.09 | 452.06 | 382.46 | |
Average Payables |
247.64 | 113.24 | 93.84 | 69.86 | |
Average Inventory |
832.35 | 971.27 | 949.15 | 976.64 | |
Average Assets |
3,656.44 | 3,322.16 | 3,434.16 | 3,329.75 | |
Average Common Equity |
1,334.18 | 1,323.91 | 1,442.59 | 1,424.49 |
Columns are period end dates · fundamentals updated 5 Nov 2026